Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III)

The State Research Center of Virology and Biotechnology “VECTOR” of the Federal Service for the Oversight of Consumer Protection and Welfare (Rospotrebnadzor) has developed the peptide-based EpiVacCorona vaccine, which is the first synthetic peptide-based antiviral vaccine for mass immunization in i...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Alexander B. Ryzhikov, Evgeny A. Ryzhikov, Marina P. Bogryantseva, Svetlana V. Usova, Elena A. Nechaeva, Elena D. Danilenko, Stepan A. Pyankov, Andrey S. Gudymo, Anastasiya A. Moiseeva, Galina S. Onkhonova, Oleg V. Pyankov, Ekaterina S. Sleptsova, Nikita V. Lomakin, Veronika S. Vasilyeva, Mikhail V. Tulikov, Vitaly G. Gusarov, Andrey A. Pulin, Maria A. Balalaeva, Svetlana B. Erofeeva, Stanislav A. Terpigorev, Olga A. Rychkova, Ivan M. Petrov, Viktoriia Y. Delian, Vladimir V. Rafalskiy, Sergey V. Tyranovets, Elena V. Gavrilova, Rinat A. Maksyutov
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2023-05-01
Edice:	Vaccines
Témata:	SARS-CoV-2 COVID-19 peptide vaccine
On-line přístup:	https://www.mdpi.com/2076-393X/11/5/998
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!